OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Gut microbiome, prebiotics, intestinal permeability and diabetes complications	79
Menopausal hormone therapy for the management of osteoporosis	74
Gut microbiome and bile acids in obesity-related diseases	70
Basics of androgen synthesis and action	61
Epidemiology and mortality of Cushing’s syndrome	61
Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression	52
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency	50
Genetics of ovarian insufficiency and defects of folliculogenesis	48
Genetic underpinnings of asthenozoospermia	46
Gut microbiome and thyroid autoimmunity	42
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	40
Genetics of teratozoospermia: Back to the head	39
Endocrine-disrupting chemicals and their effects on puberty	35
Acquisition of peak bone mass	35
Phthalates, ovarian function and fertility in adulthood	35
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	32
Genetic mutations contributing to non-obstructive azoospermia	31
Immune checkpoint inhibitor-related thyroid dysfunction	30
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications	30
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	29
Menopausal hormone therapy and breast cancer risk	29
Endocrine disruptors and the male reproductive system	28
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide	27
Endocrine disrupting chemicals and bone	27
Thyroid hormone system disrupting chemicals	27

Cardiovascular complications of mild autonomous cortisol secretion	25
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome	25
Genetics of 46,XY gonadal dysgenesis	25
Endocrine-disrupting chemicals and child health	24
Genetics of cryptorchidism and testicular regression	23
Diagnosis and management of premature ovarian insufficiency	22
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease	22
Androgens and male sexual function	22
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	22
Anaplastic thyroid cancer: An update	21
Gut microbiota and metabolic aspects of cancer cachexia	21
Cognitive health after menopause: Does menopausal hormone therapy affect it?	20
Quality of life in Cushing’s syndrome	19
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	19
Statins and diabetes: What are the connections?	19
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	19
Regulation of bone mass in inflammatory diseases	19
Prenatal exposure to phthalate esters and its impact on child development	19
Haematological actions of androgens	19
Steroid profiling in the diagnosis of mild and overt Cushing’s syndrome	18
Differentiated thyroid carcinoma: An update	18
Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases	18
Paraneoplastic autoimmune hypophysitis: An emerging concept	17
Biochemical diagnosis of Cushing’s disease: Screening and confirmatory testing	17
New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome	17
Pathophysiology of thyroid-associated orbitopathy	17
Genetics of anti-Müllerian hormone and its signaling pathway	17
Chemokines in thyroid autoimmunity	16
Immune checkpoint inhibitor-related hypophysitis	16
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy	16
Menopausal hormone therapy in women with medical conditions	15
Hypercoagulability in Cushing’s syndrome: From arterial to venous disease	15
COVID-19 vaccination and thyroiditis	15
The bidirectional interaction of COVID-19 infections and lipoproteins	15
Hormone therapy and cardiovascular disease: Benefits and harms	15
Gut microbiota and their metabolites in cardiovascular disease	15
Infertility considerations in klinefelter syndrome: From origin to management	15
Auto-immunity and the gut microbiome in type 1 diabetes: Lessons from rodent and human studies	15
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	15
Neural regulation of bone marrow adipose tissue	14
Active surveillance of low-risk papillary thyroid microcarcinoma	14
The definition of remission and recurrence of Cushing’s disease	14
Effects of endocrine disorders on lipids and lipoproteins	13
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	13
Endocrine-disrupting chemicals and behaviour: A high risk to take?	13
COVID-induced thyroid autoimmunity	13
Temozolomide in aggressive pituitary tumours and pituitary carcinomas	13
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses	13
Primary hyperparathyroidism	13